Metabolic imaging in the diagnosis of brain tumors

Current Opinion in Neurology

Volumn 9, Issue 6, 1996, Pages 429-435

  Slosman, Daniel O ^a   Lazeyras, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LIPID;

BRAIN TUMOR; DIFFERENTIAL DIAGNOSIS; HUMAN; IMAGING; MACROMOLECULE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BIOPSY;

EID: 0030455757     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199612000-00006     Document Type: Review

References (46)

1. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The (14C) deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977, 28:897-916.
2. Pellerin L, Magistretti PJ: Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 1994, 91:10625-10629.
3. Takahashi S, Driscoll BF, Law MJ, Sokoloff L: Role of sodium and potassium ions in regulation of glucose metabolism in cultured astroglia. Proc Natl Acad Sci USA 1995, 92:4616-4620.
4. Tsacopoulos M, Magistretti PJ: Metabolic coupling between glia and neurons. J Neurosci 1996, 16:877-885. This review contributes very importantly by demonstrating the new concept of neuronal activation, glucose consumption and neuron-astrocyte interactions.
5. Tyler JL, Diksic M, Villemure J-G, Evans AC, Meyer E, Yamamoto YL, Feindel W: Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987, 28:1123-1133.
6. Mineura K, Sasjima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, Uemura K: Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 1994, 73:2386-2394.
7. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM: Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995, 195:47-52.
8. Olivero WC, Dulebohn SC, Lister JR: The use of PET in evaluating patients with primary brain tumors: is it useful? J Neurol Neurosurg Psychiatry 1995, 57:250-252.
9. Kubota R, Yamada S, Kubota K: Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992, 33:1972-1980.
10. Slosman DO, Pittet N, Donath A, Polla BS: Fluorodeoxyglucose cell incorporation as an index of cell proliferation: evaluation of accuracy in cell culture. Eur J Nucl Med 1993, 20:1084-1088.
11. Slosman DO, Pugin J: Lack of correlations between 3-H deoxyglucose, 201-TI and 99m-Tc-MIBI cell incorporation under various cell stresses. J Nucl Med 1994, 35:120-126.
12. Higashi K, Clavo AC, Wahl RL: In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993, 34:773-779.
13. Minn H, Clavo AC, Grénman R, Wahl RL: In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995, 36:252-258.
14. Pruin J, Willemsen ATM, Molenaar WM, van Waarde A, Paans AMJ, Heesters MAAM, Go KG, Visser GM, Franssen EJF, Vaalburg W: Brain tumors: L-(1-C-11)tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 1995, 197:221-226.
15. Roeckle U, Radü EW, von Ammon K, Hausmann O, Maguire RP, Leenders KL: Alteration of blood-brain barrier in human brain tumors: comparison of (F18)fluorodeoxyglucose, (C11)methionine and rubidium-82 using PET. J Neurol Sci 1995, 132:20-27.
16. Hoffman JM, Waskin HA, Schifter T: FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993, 34:567-575.
17. Levivier M, Goldman S, Bidaut L, Luxen A, Stanus E, Przedborski S, BalÇriaux D, Hildebrand J, Brotchi J: Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 1992, 31:792-797.
18. Mountz JM, Raymond PA, McKeever PE, Modell JG, Hood TW, Barthel LK, Stafford-Schuck KA: Specific localization of thallium 201 in human high-grade astrocytoma by microautoradiography. Cancer Res 1989, 49:4053-4056.
19. Kosuda S, Fujii H, Aoki S, Suzuki K, Tanaka Y, Nakamura O, Shitara N: Prediction of survival in patients with suspected recurrent cerebral tumors by quantitative thallium-201 single photon emission computed tomography. Int J Radiation Oncology Biol Phys 1994, 30:1201-1206.
20. Black KL, Hoh C, Hawkins RA, Mazziotta J, Becker DP: Thallium-201 SPECT and positron emission tomography equal predictors of glioma grade and recurrence. Neurol Res 1994, 16:93-96.
21. Ruiz A, Ganz WI, Post MJD, Camp A, Landy H, Mallin W, Sfakianakis GN: Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. Am J Neuroradiol 1994, 15:1885-1894.
22. Oriuchi N, Tomiyoshi K, Inoue T, Ahmad K, Sarwar M, Tokunaga M, Suzuki H, Watanabe N, Hirano T, Shibasaki T et al.: Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med 1996, 37:457-462.
23. Lorberboym M, Baram J, Feibel M, Hercbergs A, Lieberman L: A prospective evaluation of thallium-201 single photon emission computerized tomography for brain tumor burden. Int J Radiation Oncology Biol Phys 1995, 32:249-254.
24. Rollins NK, Lowry PA, Shapiro KN: Comparison of gadolinium-enhanced MR and thallium-201 single photon emission computed tomography in pediatric brain tumors. Pediatr Neurosurg 1995, 22:8-14.
25. Grünwald F, Menzel C, Pietsch P, L., Hufnagel A, Biersack H-J: Increased technetium-99m-HMPAO uptake in grade II astrocytoma. J Nucl Med 1995, 36:804-806.
26. Slosman DO, Magistretti P: Biological basis of cerebral perfusion in SPECT in neurology and psychiatry.Edited by Van den Broeck S. (In press).
27. Jacquier-Sarlin M, Slosman DO, Polla A: The cellular basis of ECD brain retention. J Nucl Med 1996, 37:1694-1697.
28. Jacquier-Sarlin MR, Polla BS, Slosman DO: Oxido-reductive state: the major determinant for cellular retention of HMPAO-Tc99m. J Nucl Med 1996, 37:1694-1697.
29. Castillo M, Kwock L, Mukherji K: Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 1996, 17:1-15.
30. Barker PB, Glickson JD, Bryan RN: In vivo magnetic resonance spectroscopy of human brain tumors. Top Magn Reson Imaging 1993, 5:32-45.
31. Kuesel AC, Sutherland GR, Halliday W, Smith ICP: 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomedicine 1994, 7:149-155.
32. Chang L, McBride D, Miller BL, Cornford M, Booth RA, Buchthal SD, Ernst TM, Jenden D: Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimagmg 1995, 5:157-63.
33. 1H-MRS can be used to monitor the effect of therapy in tumors as well as in brain tissue.
34. Go KG, Kamman RL, Mooyaart EL, Heesters MA, Pruim J, Vaalburg W, Paans AM: Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography. Neuroradiology 1995, 37:198-206.
35. Sijens PE, Knopp MV, Brunetti A, Wicklow K, Alfano B, Bachert P, Sanders JA, Stillman AE, Kett H, Sauter R, Oudkerk M: 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med 1995, 33:818-26.
36. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, Heerschap A, Kamada K, Lee BCP, Mengeot MM et al.: Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996, 84:449-458.
37. 1H-MRS in combination with multiparametric statistical methods.
38. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK: Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995, 16:1593-1603.
39. Wang Z, Sutton LN, Cnaan A, Haselgrove JC, Rorke LB, Zhao H, Bilaniuk LT, Zimmerman RA: Proton MR spectroscopy of pediatric cerebellar tumors. AJNR Am J Neuroradiol 1995, 16:1821-1833.
40. Go KG, Keuter EJ, Kamman RL, Pruim J, Metzemaekers JD, Staal MJ, Paans AM, Vaalburg W: Contribution of magnetic resonance spectro7 scopic imaging and L-[1-11 C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery 1994, 34:994-1002.
41. Castillo M, Kwock L, Green G, Schiro S, Wilson JD, Greenwood R: Proton MR spectroscopy in a possible enhancing hamartoma in a patient with neurofibromatosis type 1. AJNR Am J Neuroradiol 1995, 16:993-996.
42. Urenjak J, Williams SR, Gadian DG, Noble M: Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993, 13:981-989.
43. Rémy C, Grand S, Sam Laï E, Belle V, Hoffmann D, Berger F, Estève F, Ziegler A, Le Bas J-F, Benabid AL et al.: 1H MRS of human brain abscesses in vivo and in vitro. Magn Reson Med 1995, 34:508-514.
44. Ott D, Hennig J, Ernst T: Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993, 186:745-752.
45. Lazeyras F, Charles HC, Boyco O, Frederiks R, Schold C, Coleman RE: New perspectives in tumor grading by combined short echo/long echo 1H spectroscopic imaging [Abstract]. Society Magnetic Resonance in Medicine; 11th Annual Meeting of the Society of Magnetic Resonance in Medicine. Vol. 2. Berlin, Germany: 1992:3604.
46. Usenius T, Usenius JP, Tenhunen M, Vainio P, Johansson R, Soimakallio S, Kauppinen R: Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1995, 33:719-24.